A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 4 analysts in the last three months, revealing a range of perspectives from bullish to bearish. The average 12-month price target is $55.5, with a high of $79.00 and a low of $42.00. Recent analyst actions include both raises and lowers in ratings and price targets.
July 25, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Rhythm Pharmaceuticals has received mixed analyst ratings over the past three months, with an average 12-month price target of $55.5. Recent actions include both raises and lowers in ratings and price targets.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on the stock price. The diverse range of perspectives indicates uncertainty among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100